問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Radiation Therapy

Division of Otolaryngology

Division of Hematology & Oncology

更新時間：2024-06-04

楊慕華Yang, Muh-Hwa
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

80Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊慕華

List

128Cases

2020-09-01 - 2023-09-20

Phase I

A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    ASP1951

Participate Sites
3Sites

Recruiting3Sites

邱昌芳
China Medical University Hospital

Division of Hematology & Oncology

2006-06-30 - 2007-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Study ended1Sites

2020-08-01 - 2022-08-31

Phase I/II

A Phase I/II, Open Label, Dose Escalation and Cohort Expansion Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of OBI 888 in Patients with Locally Advanced or Metastatic Solid Tumors.

  • Condition/Disease

    Metastatic Solid Tumors / Locally Advanced Solid Tumors

  • Test Drug

    OBI 888

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2018-02-08 - 2018-02-08

Phase III

A Randomized, Global, Open-label Study of Nivolumab in Combination With BMS-986205 vs Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

  • Condition/Disease

    Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

  • Test Drug

    BMS-986205/Nivolumab

Participate Sites
3Sites

Terminated3Sites

2014-04-01 - 2016-09-30

Phase III

Phase III Study of IV Vinflunine in Combination With Methotrexate Versus Methotrexate Alone in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-based Chemotherapy

  • Condition/Disease

    Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    Javlor

Participate Sites
7Sites

Terminated7Sites

2016-04-01 - 2018-12-04

Phase I

Phase I Study of NC-6004 in Combination with 5-FU and Cetuximab as First-line Treatment in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

  • Condition/Disease

    Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    NC-6004

Participate Sites
3Sites

Terminated3Sites

楊慕華
Taipei Veterans General Hospital

Division of Hematology & Oncology

王宏銘
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2009-10-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2020-02-29 - 2022-11-30

Phase II

Phase IIa/IIb Clinical Trial of NC-6004 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Failed Platinum or a Platinum-containing Regimen

  • Condition/Disease

    Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    NC-6004

Participate Sites
4Sites

Recruiting4Sites

1 9 10 11 12 13
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB